Last Updated:
10 Mar 2026, 03:29:48 PM (IST)
Orchid Pharma Limited
NSE: ORCHPHARMA BSE: ORCHPHARMA
NSE
509.55
10.60 (2.12%)
Prev Close
498.95
Open Price
500
Volume
191,509
Today Low / High
500 / 519.7
52 WK Low / High
489 / 904.9
Range
484 - 535
BSE
510.15
11.25 (2.25%)
Prev Close
498.9
Open Price
505.95
Volume
2,230
Today Low / High
504.85 / 519
52 WK Low / High
488.8 / 899
Range
485 - 536
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 509.55 (target range: 484 - 535), reflecting a change of 10.6 (2.12446%). On the BSE, it is listed at 510.15 (target range: 485 - 536), showing a change of 11.25 (2.25496%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
02 Mar
614.00
-2.26%
27 Feb
625.00
-0.84%
26 Feb
635.65
-1.27%
25 Feb
650.25
-3.02%
24 Feb
665.95
-2.71%
23 Feb
668.80
-0.52%
20 Feb
669.35
-0.18%
19 Feb
679.45
-1.40%
18 Feb
664.75
-0.08%
Orchid Pharma Limited Graph
Orchid Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Orchid Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 509.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 510.15 | 515.25 | 463.73 - 566.78 |
| 520.35 | 416.28 - 624.42 | ||
| 525.45 | 367.82 - 683.09 | ||
| Bearish Scenario | 510.15 | 505.05 | 454.54 - 555.55 |
| 499.95 | 399.96 - 599.94 | ||
| 494.85 | 346.39 - 643.30 |
Overview of Orchid Pharma Limited
ISIN
INE191A01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
56,848
Market Cap
30,436,534,911
Last Dividend
0
Official Website
IPO Date
2002-07-01
DCF Diff
445.04
DCF
155
Financial Ratios Every Investor Needs
Stock Dividend of ORCHPHARMA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2012-09-13 | September 13, 12 | 3 | 0.0138 | |||
| 2011-07-19 | July 19, 11 | 3 | 0.0138 | |||
| 2010-07-12 | July 12, 10 | 10 | 0.0459 | |||
| 2009-09-17 | September 17, 09 | 1 | 0.0046 | |||
| 2008-09-18 | September 18, 08 | 3 | 0.0138 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 921.93 Cr | 567.16 Cr | 354.76 Cr | 0.3848 | 8.37 Cr | 0.00 Cr | 81.11 Cr | 99.66 Cr | 19.65 | 144.65 Cr | 0.1081 |
| 2024-03-31 | 819.07 Cr | 682.91 Cr | 136.15 Cr | 0.1662 | 7.09 Cr | 8.43 Cr | 77.70 Cr | 92.17 Cr | 19.06 | 141.92 Cr | 0.1125 |
| 2023-03-31 | 665.90 Cr | 595.21 Cr | 70.69 Cr | 0.1062 | 6.36 Cr | 8.79 Cr | 29.67 Cr | 46.32 Cr | 11.35 | 142.94 Cr | 0.0696 |
| 2022-03-31 | 559.56 Cr | 327.09 Cr | 232.47 Cr | 0.4154 | 6.63 Cr | 8.64 Cr | -33.89 Cr | -1.95 Cr | -0.48 | 62.14 Cr | -0.0035 |
| 2021-03-31 | 450.06 Cr | 241.30 Cr | 208.76 Cr | 0.4638 | 4.81 Cr | 12.90 Cr | -50.49 Cr | -116.53 Cr | -28.55 | 65.00 Cr | -0.2589 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 21.11 Cr | 1,687.91 Cr | 420.63 Cr | 1,267.2854 Cr | 174.61 Cr | 153.50 Cr | 326.37 Cr | 696.41 Cr | 0.00 Cr | 0.00 Cr | 49.69 Cr | 285.5696 Cr |
| 2024-03-31 | 3.60 Cr | 1,553.87 Cr | 384.41 Cr | 1,169.4661 Cr | 135.18 Cr | 131.58 Cr | 264.23 Cr | 645.12 Cr | 0.00 Cr | 0.00 Cr | 45.84 Cr | 259.9743 Cr |
| 2023-03-31 | 22.60 Cr | 1,225.21 Cr | 536.56 Cr | 688.6490 Cr | 331.35 Cr | 308.75 Cr | 228.74 Cr | 619.17 Cr | 1.68 Cr | 0.00 Cr | 44.44 Cr | 371.8917 Cr |
| 2022-03-31 | 4.31 Cr | 1,110.56 Cr | 463.18 Cr | 647.3799 Cr | 267.95 Cr | 263.65 Cr | 172.66 Cr | 604.82 Cr | 0.00 Cr | 0.00 Cr | 45.50 Cr | 240.7783 Cr |
| 2021-03-31 | 15.69 Cr | 1,237.25 Cr | 584.34 Cr | 652.9078 Cr | 452.74 Cr | 437.05 Cr | 152.89 Cr | 677.51 Cr | 0.04 Cr | 0.00 Cr | 0.42 Cr | 142.0818 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 19.2151 Cr | -26.9309 Cr | 25.2217 Cr | -130.8929 Cr | 17.5059 Cr | 21.1068 Cr | -150.1080 Cr | 99.4633 Cr | 28.3351 Cr | 0.0000 Cr | -62.1454 Cr |
| 2024-03-31 | 125.9920 Cr | -312.0286 Cr | 167.0404 Cr | 61.1772 Cr | -18.9962 Cr | 3.6009 Cr | -64.8148 Cr | 92.1665 Cr | -208.5472 Cr | 0.0000 Cr | -35.4881 Cr |
| 2023-03-31 | 18.3380 Cr | -31.2139 Cr | 31.1664 Cr | -66.5751 Cr | 18.2905 Cr | 22.5971 Cr | -84.9131 Cr | 46.3183 Cr | 63.3921 Cr | 0.0000 Cr | -56.0817 Cr |
| 2022-03-31 | 92.4746 Cr | 112.9362 Cr | -216.7981 Cr | 78.0711 Cr | -11.3873 Cr | 4.3066 Cr | -14.4035 Cr | -1.9512 Cr | -184.7864 Cr | 0.0000 Cr | 2.5369 Cr |
| 2021-03-31 | 23.5860 Cr | 67.2051 Cr | -164.9887 Cr | 22.9820 Cr | -74.1976 Cr | 15.6939 Cr | -0.6040 Cr | -116.5300 Cr | -125.0800 Cr | 0.0000 Cr | -33.4985 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | 207.27 Cr | 143.15 Cr | 64.12 Cr | 0.3094 | 30.96 Cr | -12.61 Cr | -2.49 | 0.06 Cr | -0.0609 |
| 2025-09-30 | 193.52 Cr | 132.51 Cr | 61.02 Cr | 0.3153 | -10.38 Cr | -5.72 Cr | -1.13 | 9.30 Cr | -0.0296 |
| 2025-06-30 | 172.93 Cr | 98.87 Cr | 74.06 Cr | 0.4283 | 5.52 Cr | 14.91 Cr | 2.94 | 25.62 Cr | 0.0862 |
| 2025-03-31 | 237.48 Cr | 138.02 Cr | 99.46 Cr | 0.4188 | 19.11 Cr | 22.29 Cr | 4.40 | 31.88 Cr | 0.0939 |
| 2024-12-31 | 217.34 Cr | 124.79 Cr | 92.55 Cr | 0.4258 | 61.89 Cr | 20.78 Cr | 4.10 | 34.85 Cr | 0.0956 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 41.99 Cr | 107.59 Cr | 149.58 Cr | 202.17 Cr | 306.22 Cr | 704.68 Cr | 735.54 Cr | 1,722.05 Cr | 448.21 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 179.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,267.29 Cr |
| 2025-03-31 | 21.11 Cr | 155.41 Cr | 182.68 Cr | 241.83 Cr | 326.37 Cr | 807.42 Cr | 696.41 Cr | 1,687.91 Cr | 420.63 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 243.89 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,224.24 Cr |
| 2024-09-30 | 4.35 Cr | 243.59 Cr | 247.94 Cr | 215.20 Cr | 320.58 Cr | 833.37 Cr | 656.15 Cr | 1,635.14 Cr | 410.90 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 14.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 22.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 20.78 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 27.24 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 29.35 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2019-07-25 | July 25, 19 | 1:218 |
| 2005-09-15 | September 15, 05 | 3:2 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,812.80 | ₹4,349,514,433,616.00 | ₹3,298,187.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,372.00 | ₹1,691,565,791,760.00 | ₹298,134.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,427.80 | ₹1,498,568,719,232.00 | ₹373,853.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,314.60 | ₹1,094,510,791,983.00 | ₹2,328,593.00 |
| Lupin Limited | LUPIN | ₹2,337.40 | ₹1,068,292,308,200.00 | ₹1,118,737.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹923.10 | ₹928,854,596,169.00 | ₹548,985.00 |
| Mankind Pharma Limited | MANKIND | ₹2,237.70 | ₹923,733,909,614.00 | ₹1,043,890.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,285.90 | ₹746,852,807,016.00 | ₹2,197,557.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,616.50 | ₹671,536,822,500.00 | ₹127,559.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,225.80 | ₹628,122,560,672.00 | ₹1,554,299.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,038.00 | ₹560,371,132,116.00 | ₹1,367,251.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,491.20 | ₹378,323,729,882.00 | ₹56,999.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,999.90 | ₹374,794,378,438.00 | ₹123,025.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,117.40 | ₹339,967,004,084.00 | ₹706,890.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,567.80 | ₹297,211,828,212.00 | ₹871,597.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,815.50 | ₹220,387,500,000.00 | ₹3,477.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,327.40 | ₹215,692,105,131.00 | ₹576,727.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹1,039.20 | ₹186,130,976,904.00 | ₹2,029,982.00 |
| Eris Lifesciences Limited | ERIS | ₹1,351.10 | ₹184,042,641,430.00 | ₹100,690.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹12,597.00 | ₹161,618,111,733.00 | ₹24,766.00 |
| Granules India Limited | GRANULES | ₹581.30 | ₹141,063,489,700.00 | ₹712,670.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹712.35 | ₹140,021,741,381.00 | ₹50,451.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹812.35 | ₹128,651,664,788.00 | ₹293,109.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,684.10 | ₹128,011,297,234.00 | ₹43,345.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹940.65 | ₹115,451,618,400.00 | ₹42,515.00 |
| Cohance Lifesciences Limited | COHANCE | ₹295.60 | ₹113,086,846,584.00 | ₹907,550.00 |
| Viyash Scientific Limited | VIYASH | ₹197.45 | ₹86,151,137,188.00 | ₹1,162,070.00 |
| Procter & Gamble Health Limited | PGHL | ₹4,892.10 | ₹81,205,836,682.00 | ₹11,986.00 |
| Strides Pharma Science Limited | STAR | ₹872.90 | ₹80,457,562,051.00 | ₹160,822.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹500.60 | ₹76,642,890,235.00 | ₹265,090.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹338.65 | ₹66,233,781,988.00 | ₹758,443.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹686.70 | ₹62,254,676,925.00 | ₹118,363.00 |
| FDC Limited | FDC | ₹378.05 | ₹61,550,352,256.00 | ₹52,686.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹124.37 | ₹40,360,749,900.00 | ₹1,617,219.00 |
| Innova Captab Limited | INNOVACAP | ₹703.35 | ₹40,249,153,812.00 | ₹21,279.00 |
| Suven Life Sciences Limited | SUVEN | ₹144.43 | ₹33,500,801,218.00 | ₹421,279.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹301.45 | ₹32,847,579,134.00 | ₹64,137.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹353.45 | ₹32,259,381,500.00 | ₹243,536.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,908.60 | ₹31,566,364,029.00 | ₹7,443.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹289.65 | ₹29,046,827,863.00 | ₹71,884.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹509.55 | ₹25,843,919,953.00 | ₹191,509.00 |
Key Executives
Vice President of Operations
A. Chandrasekar
Gender: Not Specified
Year Born:
Head of CTD & IPM
S. Srinivasan
Gender: Not Specified
Year Born: 1971
Head of Human Resources
Ashok Clifford D
Gender: male
Year Born: 1973
Company Secretary & Compliance Officer
Kapil Dayya
Gender: male
Year Born:
MD & Director
Manish Dhanuka
Gender: male
Year Born: 1967
Whole Time Director
Mridul Dhanuka
Gender: male
Year Born: 1980
Head of Medico Marke
Prabhu Vinayagam
Gender: male
Year Born: 1970
Head of Information Technology
Praga Kumar Patro
Gender: male
Year Born: 1975
President of API, CSR and SH & E
Sivaswami Mani
Gender: male
Year Born: 1960
Chief Financial Officer
Sunil Kumar Gupta
Gender: male
Year Born: 1963
FAQs about Orchid Pharma Limited
Who is the CEO of the company?
The CEO is Manish Dhanuka.
What is the current market price of the stock?
The current price is ₹600.10.
What is the 52-week price range?
The range is ₹595-979.95.
What is the market capitalization of the company?
The market capitalization is ₹3,043.65 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 161.11.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Orchid Pharma Limited (ISIN: INE191A01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹3,043.65 crores and an average daily volume of 56,848 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.